Table 4.

Results of the Cox's model

VariableUnadjustedAdjusteda
HR (95% CI)PHR (95% CI)P
Occurrence of acute kidney injury2.73 (2.09 to 3.58)<0.012.40 (1.80 to 3.20)<0.01
Time with CD4 >200 cells/mm3a0.48 (0.38 to 0.61)<0.010.63 (0.48 to 0.81)0.03
Time with VL <500 copies/mla1.02 (0.82 to 1.27)0.850.88 (0.69 to 1.11)0.27
Occurrence of an AIDS-defining event1.73 (1.369 to 2.19)<0.011.19 (0.93 to 1.54)0.17
Hepatitis B1.34 (0.94 to 1.91)0.111.13 (0.78 to 1.63)0.53
Hepatitis C0.90 (0.69 to 1.17)0.421.07 (0.81 to 1.41)0.65
Hypertension4.36 (3.52 to 5.39)<0.012.39 (1.88 to 3.04)<0.01
Diabetes2.52 (1.75 to 3.62)<0.011.23 (0.84 to 1.80)0.30
Past exposure
    AZT1.12 (0.85 to 1.47)0.430.88 (0.62 to 1.26)0.48
    3TC1.67 (1.14 to 2.45)0.090.89 (0.52 to 1.51)0.89
    ABC1.25 (0.88 to 1.77)0.220.92 (0.62 to 1.36)0.67
    DDI1.09 (0.86 to 1.39)0.480.84 (0.63 to 1.23)0.25
    DDC1.01 (0.77 to 1.32)0.950.93 (0.69 to 1.26)0.64
    D4T1.15 (0.90 to 1.48)0.270.93 (0.67 to 1.29)0.67
    TDF2.61 (1.69 to 4.04)<0.012.23 (1.37 to 3.63)0.01
    FTC1.41 (0.20 to 10.13)0.731.03 (0.14 to 7.66)0.98
    SQV0.98 (0.70 to 1.37)0.880.74 (0.51 to 1.08)0.12
    IDV1.38 (1.08 to 1.77)0.011.28 (0.97 to 1.70)0.08
    NFV0.85 (0.63 to 1.15)0.300.78 (0.56 to 1.09)0.15
    LPV1.40 (0.92 to 2.12)0.111.04 (0.66 to 1.64)0.88
    ATV2.06 (0.75 to 5.63)0.161.24 (0.43 to 3.55)0.69
    FAPV1.38 (0.75 to 2.55)0.300.93 (0.47 to 1.84)0.83
    NVP0.83 (0.60 to 1.16)0.270.75 (0.52 to 1.09)0.13
    EFV1.13 (0.83 to 1.53)0.441.00 (0.72 to 1.40)0.99
Recent exposure
    AZT0.78 (0.59 to 1.04)0.100.62 (0.42 to 0.91)0.02
    3TC1.77(1.27 to 2.45)0.011.24 (0.76 to 2.04)0.39
    ABC1.40 (1.08 to 1.81)0.121.37 (1.03 to 1.82)0.03
    DDI0.77 (0.55 to 1.07)0.120.75 (0.52 to 1.08)0.13
    DDC0.33 (0.12 to 0.91)0.030.40 (0.14 to 1.14)0.09
    D4T1.56 (1.15 to 2.11)0.041.17 (0.81 to 1.70)0.4
    TDF1.67 (1.24 to 2.31)0.011.55 (1.09 to 2.20)0.02
    FTC1.06 (0.56 to 2.00)0.850.94 (0.47 to 1.89)0.87
    SQV1.04 (0.66 to 1.63)0.880.94 (0.59 to 1.51)0.8
    IDV2.32 (1.68 to 3.21)<0.012.03 (1.42 to 2.90)<0.01
    NFV0.94 (0.58 to 1.53)0.800.96 (0.58 to 1.59)0.87
    LPV1.36 (0.99 to 1.85)0.051.30 (0.92 to 1.85)0.14
    ATV1.77 (1.18 to 2.65)0.061.47 (0.94 to 2.30)0.09
    FAPV0.75 (0.42 to 1.35)0.340.72 (0.39 to 1.32)0.29
    NVP0.96 (0.69 to 1.33)0.801.08 (0.76 to 1.54)0.68
    EFV0.97 (0.70 to 1.35)0.851.02 (0.71 to 1.46)0.92
  • a Values after adjustment for age, gender, BMI, time since HIV diagnosis, cumulative exposure to any ART, and number of ART drugs received. 3TC, lamivudine; ABC, abacavir; DDI, didanosine; DDC, zalcitabine; D4T, stavudine; TDF, tenofovir; FTC, emtricitabine; NVP, névirapine; EFV, efavirenz; FAPV, fosAmprenavir; SQV, saquinavir; IDV, indinavir; NFV, nelfinavir; LPV, lopinavit; ATV, atazanavir. Bold values indicated statistically significant difference.